House dust mite allergy exacerbates psoriasis by promoting hyperactivation of mast cells and Th17 cells
- PMID: 40795502
- DOI: 10.1016/j.intimp.2025.115336
House dust mite allergy exacerbates psoriasis by promoting hyperactivation of mast cells and Th17 cells
Abstract
Accumulating evidence has linked environmental factors, such as allergens, to the exacerbation of psoriasis through effects on immune responses. This study assessed the impact of house dust mite (HDM) allergy-one of the most prevalent allergens-on the severity of psoriasis using retrospective patient analyses and experimental models. Clinically, patients with allergies demonstrated significantly increased psoriasis severity, as determined by medication usage. In vitro, HaCaT cells co-stimulated with interleukin (IL)-17A and histamine exhibited synergistically elevated production of pro-inflammatory cytokines IL-6 and Il36g via the activation of the MAPK/NF-κB signaling pathway, as confirmed by ELISA and immunoblotting. Additionally, the co-stimulation increased IL-17RA expression, as confirmed by immunoblotting. In vivo, C57BL/6 mice sensitized and challenged with HDM were subsequently treated with imiquimod (IMQ) to induce psoriasis-like dermatitis, resulting in aggravated psoriatic phenotypes as evidenced by higher Psoriasis Severity Index (PSI) scores and increased epidermal thickness observed in skin biopsies. These effects were associated with enhanced differentiation and activation of T-helper (Th)2 and Th17 cells, as revealed by flow cytometry, as well as increased mast cell activation in skin biopsies, indicating an amplified inflammatory response driven by HDM allergy. These findings underline the role of HDM allergy in intensifying psoriasis, mediated by complex immune interactions involving Th17 cells and mast cells, suggesting managing environmental allergens and targeting these pathways could offer potential strategies to mitigate the severity of psoriasis.
Keywords: House dust mite; Imiquimod-induced psoriasis-like dermatitis murine model; Mast cell; Psoriasis; Th17 cell.
Copyright © 2025. Published by Elsevier B.V.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
CYSLTR1 antagonist inhibits Th17 cell differentiation by regulating the NF-κB signaling for the treatment of psoriasis.Int J Biol Sci. 2024 Mar 25;20(6):2168-2186. doi: 10.7150/ijbs.92514. eCollection 2024. Int J Biol Sci. 2024. PMID: 38617532 Free PMC article.
-
Upregulated miR-374a-5p drives psoriasis pathogenesis through WIF1 downregulation and Wnt5a/NF-κB activation.Cell Signal. 2024 Jul;119:111171. doi: 10.1016/j.cellsig.2024.111171. Epub 2024 Apr 9. Cell Signal. 2024. PMID: 38604345
-
Imiquimod promotes Th1 and Th17 responses via NF-κB-driven IL-12 and IL-6 production in an in vitro co-culture model.Exp Ther Med. 2025 Jul 21;30(3):175. doi: 10.3892/etm.2025.12925. eCollection 2025 Sep. Exp Ther Med. 2025. PMID: 40746447 Free PMC article.
-
House dust mite reduction and avoidance measures for treating eczema.Cochrane Database Syst Rev. 2015 Jan 19;1(1):CD008426. doi: 10.1002/14651858.CD008426.pub2. Cochrane Database Syst Rev. 2015. PMID: 25598014 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
LinkOut - more resources
Full Text Sources